Niagen Bioscience, Inc. (NAGE) fair value analysis
Nasdaq · Updated 2026-10-19
NAGE price how computed
Valuation status
No fair-value estimate yetNAGE has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for NAGE yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $2.49
- Sector
- Healthcare
- 12-month range
- $2.49–$7.60
- Market cap
- $197M
- From 52-week high
- -67.2%
- Shares outstanding
- 79.1M
- Rank in Healthcare by quality score
- #35 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Niagen Bioscience, Inc. is a healthcare company that develops and commercializes nicotinamide riboside products and related nutritional supplements. The company operates in the United States and serves customers through direct-to-consumer and retail distribution channels.
NAGE currently ranks #35 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $197M
- P/E (trailing)
- 23x
- Revenue (TTM)
- $129M
- Net margin
- 12.4%
- EPS (TTM)
- $0.11
- Gross margin
- 64.8%
- Debt / equity
- 0.03
- Revenue growth (3-yr avg)
- 17.6%
- Shares outstanding
- 79.1M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Stable
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 29 · oversold
- 50-day average
- $2.98
- 200-day average
- $4.12
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-11-04 (post-market)
- Last 8 quarters vs consensus
- 6 beat, 1 missed
- Quarter by quarter
- 2026-06 ▬ met (0.0%)
2026-03 ▼ miss (-66.7%)
2025-12 ▲ beat (+25.5%)
2025-09 ▲ beat (+150.0%)
2025-06 ▲ beat (+300.0%)
2025-03 ▲ beat (+150.0%)
2024-12 ▲ beat (+350.0%)
2024-09 ▲ beat (+100.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 6 buy · 0 hold · 0 sell (6 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $12.1
- Target vs last price
- +385.9%
What our data shows for NAGE
- Shares are trading in the lower third of their 12-month price range of $2.49–$7.60.
- The 14-day relative strength index sits at an oversold 29.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- NAGE's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the NAGE conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TickrTrends' derived indicators for NAGE showed notable shifts this week within the Healthcare sector. The Relative Strength Index zone moved from neutral to oversold, while the valuation verdict transitioned from Undervalued to awaiting full valuation. These changes reflect evolving technical and fundamental assessments of the stock during this period.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — TickrTrends' derived indicators for NAGE show movement in sector valuation positioning this week. The sector discount rank improved from 47 to 38, indicating a shift toward relatively better valuation within the Healthcare sector. NAGE maintains an Undervalued verdict based on current analysis.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is NAGE stock undervalued?
TickrTrends has no fair-value estimate for NAGE yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is NAGE's TickrTrends verdict?
NAGE is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does NAGE compare to other Healthcare stocks?
NAGE ranks #35 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is NAGE overbought or oversold?
NAGE's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does NAGE report earnings next?
NAGE's next earnings report is scheduled for 2026-11-04 (post-market), per the published earnings calendar.
Does NAGE usually beat earnings estimates?
Over its last 8 reported quarters NAGE beat the consensus estimate 6 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about NAGE?
Of 6 analysts covering NAGE, 6 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $12.1 (+385.9% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.